SCHEMBL306514

SCHEMBL306514

CC1(C)C2CC[C@]1(CS(=O)(=O)N1CO1)C(=O)C2

nearest known ligand 0.67

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.67
KMT2A Q03164 4/20 0.63
MEN1 O00255 3/20 0.63
KDM4E B2RXH2 1/20 0.59
ALDH1A1 P00352 2/20 0.56
F2 P00734 2/20 0.55
PRSS1 P07477 2/20 0.55
PRSS2 P07478 2/20 0.55
PRSS3 P35030 2/20 0.55
TSHR P16473 1/20 0.53
HSD17B10 Q99714 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
CYP1A2 P05177 1/20 0.52
CYP2C19 P33261 1/20 0.52
CXCR3 P49682 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1603596 1.00 SMN1; SMN2 (0.67) SMN1; SMN2KMT2AMEN1KDM4EALDH1A1
SCHEMBL416659 1.00 SMN1; SMN2 (0.67) SMN1; SMN2KMT2AMEN1KDM4EALDH1A1
SCHEMBL158053 1.00 SMN1; SMN2 (0.67) SMN1; SMN2KMT2AMEN1KDM4EALDH1A1
SCHEMBL29652034 0.83 SMN1; SMN2 (0.48) SMN1; SMN2KMT2AMEN1KDM4EALDH1A1
SCHEMBL362333 0.83 SMN1; SMN2 (0.48) SMN1; SMN2KMT2AMEN1KDM4EALDH1A1
SCHEMBL6337655 0.83 SMN1; SMN2 (0.48) SMN1; SMN2KMT2AMEN1KDM4EALDH1A1
SCHEMBL6335926 0.83 SMN1; SMN2 (0.48) SMN1; SMN2KMT2AMEN1KDM4EALDH1A1
SCHEMBL6842010 0.83 SMN1; SMN2 (0.48) SMN1; SMN2KMT2AMEN1KDM4EALDH1A1
SCHEMBL29040265 0.83 SMN1; SMN2 (0.82) SMN1; SMN2KMT2AMEN1KDM4EL3MBTL1
SCHEMBL11623286 0.83 SMN1; SMN2 (0.82) SMN1; SMN2KMT2AMEN1KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868194-B2 Process for the preparation of 21-hydroxy steroids with control of the epimeric distribution at the C-21 position INDUSTRIALE CHIMICA S.R.L. (IT) 2011-01-11 US claimed
EP-1809649-B1 PROCESS FOR THE PREPARATION OF 21-HYDROXY STEROIDS WITH CONTROL OF THE EPIMERIC DISTRIBUTION AT THE C-21 POSITION IND CHIMICA SRL (IT) 2010-03-17 EP claimed
US-20080114180-A1 Process for the Preparation of 21-Hydroxy Steroids with Control of the Epimeric Distribution at the C-21 Position INDUSTRIALE CHIMICA S.R.L. (IT) 2008-05-15 US claimed
EP-1809649-A1 PROCESS FOR THE PREPARATION OF 21-HYDROXY STEROIDS WITH CONTROL OF THE EPIMERIC DISTRIBUTION AT THE C-21 POSITION INDUSTRIALE CHIMICA S.r.l. (IT) 2007-07-25 EP claimed
US-20070010676-A1 Stereospecific enrichment of heterocyclic enantiomers R.T. ALAMO VENTURES I, LLC 2007-01-11 US claimed
US-7084275-B2 Stereospecific enrichment of heterocyclic enantiomers R. T. ALAMO VENTURES I, LLC (US) 2006-08-01 US claimed
WO-2006045745-A1 PROCESS FOR THE PREPARATION OF 21-HYDROXY STEROIDS WITH CONTROL OF THE EPIMERIC DISTRIBUTION AT THE C-21 POSITION INDUSTRIALE CHIMICA S.R.L. (IT) 2006-05-04 WO claimed
US-20040220218-A1 Chlorinated heterocyclic compounds and methods of synthesis R.T. ALAMO VENTURES I, LLC 2004-11-04 US claimed
US-20040215016-A1 Stereospecific enrichment of heterocyclic enantiomers R.T. ALAMO VENTURES I, LLC 2004-10-28 US claimed
US-6730790-B2 INCLUDING RACEMIC MONOCHLOROFLOSEQUINAN, PURIFIED ENANTIOMERS OF MONOCHLOROFLOSEQUINAN AND SULFONE DERIVATIVE OF MONOCHLOROFLOSEQUINAN R.T. ALAMO VENTURES I. LLC 2004-05-04 US claimed
US-6649764-B2 Racemization of flusequinan using triphenylphosphine and 10-camphorsulfonyl-oxaziridine to form racemic mixtures R. T. ALAMO VENTURES I, LLC 2003-11-18 US claimed
US-20030166677-A1 CHLORINATED HETEROCYCLIC COMPOUNDS AND METHODS OF SYNTHESIS R.T. ALAMO VENTURES I, LLC 2003-09-04 US claimed
US-20030120075-A1 Stereospecific enrichment of heterocyclic enantiomers R.T. ALAMO ADVENTURES I, LLC 2003-06-26 US claimed
US-12479830-B2 Homopiperazinyl and homopiperidinyl quinazolin-4(3H)-one derivatives having multimodal activity against pain ESTEVE PHARMACEUTICALS, S.A. (ES) 2025-11-25 US disclosed
WO-2025235761-A1 REAGENTS AND PROCESSES FOR PREPARING OLIGONUCLEOTIDES BIOGEN MA INC. (US) 2025-11-13 WO disclosed
EP-4588908-A1 NEW PROSTACYCLIN FOR TREATING PULMONARY HYPERTENSION Shanghai Forefront Pharma Co., Ltd. (CN) 2025-07-23 EP disclosed
WO-1996025405-A1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-08-22 WO disclosed
EP-0710223-A4 SYNTHESIS OF TAXOL AND ITS DERIVATIVES UNIV FLORIDA STATE (US) 1996-08-21 EP disclosed
EP-0710223-A1 SYNTHESIS OF TAXOL AND ITS DERIVATIVES FLORIDA STATE UNIVERSITY (US) 1996-05-08 EP disclosed
WO-1995003265-A1 SYNTHESIS OF TAXOL AND ITS DERIVATIVES FLORIDA STATE UNIVERSITY (US) 1995-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220218-A1 Chlorinated heterocyclic compounds and methods of synthesis STS, SCLY, HCCS SMN1; SMN2 4873/4885KMT2A 1092/4885MEN1 1262/4885
US-20030166677-A1 CHLORINATED HETEROCYCLIC COMPOUNDS AND METHODS OF SYNTHESIS STS, SCLY, HCCS SMN1; SMN2 4873/4885KMT2A 1092/4885MEN1 1262/4885
US-20070010676-A1 Stereospecific enrichment of heterocyclic enantiomers CBR3, CBR1, QDPR SMN1; SMN2 3859/4885KMT2A 3308/4885MEN1 3511/4885
US-12479830-B2 Homopiperazinyl and homopiperidinyl quinazolin-4(3H)-one derivatives having multimodal activity against pain OPRD1, SIGMAR1, OPRK1 SMN1; SMN2 2559/4885KMT2A 4116/4885MEN1 4434/4885
US-20080114180-A1 Process for the Preparation of 21-Hydroxy Steroids with Control of the Epimeric Distribution at the C-21 Position CYP17A1, CYP21A2, HSD17B7 SMN1; SMN2 3303/4885KMT2A 2463/4885MEN1 303/4885
US-20040215016-A1 Stereospecific enrichment of heterocyclic enantiomers CBR3, POR, CBR1 SMN1; SMN2 3953/4885KMT2A 3103/4885MEN1 3536/4885
US-20030120075-A1 Stereospecific enrichment of heterocyclic enantiomers CBR3, POR, CBR1 SMN1; SMN2 3953/4885KMT2A 3103/4885MEN1 3536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.